First-in-Human Trial Reports Promising Dual Lassa–Rabies Vaccine Data

Why It Matters

A safe, bivalent vaccine could streamline immunization campaigns in West Africa, where Lassa fever and rabies co‑occur, and accelerate progress toward the first licensed Lassa vaccine. Its storage flexibility expands reach to remote, high‑risk populations, addressing a critical gap in global health security.

Key Takeaways

• First-in-human trial shows LASSARAB safe, no serious adverse events
• Vaccine generated strong antibody responses to both Lassa and rabies viruses
• Freeze‑dry formulation enables distribution without reliable cold‑chain infrastructure
• Dual vaccine could streamline immunization in West Africa where both diseases coexist
• Success could accelerate advanced trials, addressing 300k Lassa cases annually

Pulse Analysis

The emergence of Lassa fever as a climate‑driven threat has left West Africa without a licensed prophylactic, while rabies continues to claim thousands of lives annually. By leveraging an attenuated rabies virus vector to display the Lassa glycoprotein complex, the University of Maryland’s LASSARAB platform merges two high‑priority antigens into a single dose. This approach not only reduces the logistical burden of separate vaccination schedules but also taps into the extensive safety record of rabies vaccines, offering regulators a familiar pathway for approval.

In the randomized, controlled phase‑1 study, 54 volunteers received two doses of LASSARAB or a standard rabies vaccine. Interim analysis through day 61 revealed no serious adverse events and a rapid rise in neutralizing antibodies against both pathogens, surpassing the control’s rabies‑only response. The candidate’s ability to be freeze‑dried is a game‑changer for distribution in remote settings where electricity and refrigeration are scarce. This formulation could enable mass campaigns during outbreaks, aligning with WHO’s push for vaccine‑ready stockpiles in low‑resource regions.

If longer‑term follow‑up confirms durable immunity, LASSARAB could progress to phase‑2/3 trials and eventually become the first licensed Lassa vaccine. The dual‑target strategy may inspire similar platforms for other zoonotic diseases, creating a new class of combination vaccines. With climate change expanding the geographic range of Lassa‑carrying rodents, an accessible, single‑shot solution could protect an estimated 700 million people at risk, reshaping public‑health preparedness across sub‑Saharan Africa and beyond.